Turkey: The Turkish Competition Board Refuses to Grant Individual Exemption to the Exclusivity Agreement for a Key Drug

Daiichi Sankyo İlaç Ticaret Ltd. Şti. ("Daiichi"), a globally active company in the distribution, sale, marketing and importation of pharmaceutical products, and Aksel Ecza Deposu A.Ş. ("Aksel"), a drug wholesaler, entered into a vertical exclusivity agreement ("Agreement"). They jointly applied to the Turkish Competition Board ("Board") for an individual exemption to be granted to the Agreement. The Board published its reasoned decision on November 22, 2016, refusing to grant an individual exemption.

The Agreement was designed to give exclusive authority to Aksel to participate in tenders across Turkey for the drug known as Simdax1.  Simdax is used by hospitals to provide support therapy to patients who have undergone coronary bypass surgery. 

In defining the relevant product market, the Board referred to the European Pharmaceutical Marketing Association's ATC categorization. The Board asserted that an ATC-3 level categorization would not reflect the entire competitive landscape of the drug, since Levosimendan (the active substance in Simdax) carries particular features and hospital tenders are usually made on the basis of a specific drug molecule. The Board thus defined the relevant product market collectively, based on the type of sale and the active substance of the drug, and established the relevant market as, "tender of the products with the drug substance Levosimendan."

The Board noted that the Agreement did not contain any provisions that entailed resale price maintenance. However, the Board found that the exclusivity and non-compete provisions nevertheless amounted to a violation of Article 4 of Law No. 4054. The Board stated that Simdax does not have a generic substitute, and therefore, it is unrivalled in the tender sales market in terms of its active substance. Accordingly, the Board decided that the Agreement could not benefit from a block exemption under the Block Exemption Communiqué No. 2002/2 on Vertical Agreements ("Communiqué No. 2002/2"), as the supplier in this case held a market share of over 40% in the relevant market for Simdax. Since the agreement was unable to benefit from the block exemption under Communiqué No. 2002/2, the Board applied an individual exemption test to see if the Agreement was eligible for an individual exemption under the following conditions:

  1. The agreement must contribute to the improvement of the production or distribution of goods or the promotion of technical or economic progress,
  2. it must allow consumers a fair share of the resulting benefit,
  3. it should not impose on the undertakings concerned restrictions which are not indispensable to the attainment of these objectives, and
  4. it should not afford the parties the possibility of eliminating competition with respect to a substantial part of the products in question.

The Board concluded that the Agreement met the first condition, as it contributed to the improvement of the production or distribution of goods or to the promotion of technical or economic progress. The Board noted that the Agreement allowed Daiichi to effectively follow and actively participate in the tenders, and thus ensured the continued and uninterrupted provision of the product. By collecting regular information on tenders, the Agreement enabled Daiichi to adjust its production, importation and inventory planning accordingly.

For the second condition, the Board decided that the Agreement did not meet the test of allowing consumers a fair share of the resulting benefit. The Board stated that both the public health expenses and the satisfaction of hospital demands had been taken into account. The Board determined that hospital demand had largely not been met since the Agreement had entered into effect.

For the third condition, the Board concluded that it is not possible for the agreement to eliminate competition with respect to a substantial part of the products in question, since there are numerous pharmaceutical wholesalers active in Turkey.

With regard to the fourth condition, the Board decided that the agreement fell short of satisfying the test, since the Agreement restricted Aksel's participation in tenders involving products that competed with any Daiichi products. The Board noted that this clause prevented Aksel from participating in group tenders where more than one type of drug was required. Because of this clause, none of the other wholesalers could participate in a tender that includes Simdax along with other types of drugs, since the agreement also restricted Aksel's ability to sell Simdax to other wholesalers to enable them to participate in the group tenders.

Consequently, the Board decided by a majority vote that the Agreement did not meet the cumulative conditions of individual exemption under Article 5 of Law No. 4054. Therefore, the Board did not grant an individual exemption to the Agreement.

The dissenting opinion argued that the Agreement would not restrict competition in the relevant market since it included a clause that allowed Daiichi to appoint another wholesaler to procure Simdax when Aksel was not able to. Moreover, the Agreement could possibly lead to positive results after implementation in terms of the number of participated tenders and drugs transmitted to patients and hospitals. As a result, the dissenting opinion concluded that the Board should have granted an individual exemption to the Agreement.

(1)The Board's reasoned decision numbered 16-30/504-225 and dated September 8, 2016.

This article was first published in Legal Insights Quarterly by ELIG, Attorneys-at-Law in March 2017. A link to the full Legal Insight Quarterly may be found here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions